Bernard A. Fox, PhD, has served as the president and Chief Executive Officer since founding the company in 2005. He served on the board of directors of NeoPharm from 2004 to 2010, and is currently on the board of directors of the Oregon Bioscience Association. Dr. Fox also co-founded UbiVac-CMV, a company developing cytomegalovirus vectors as vaccines for cancer. A recognized expert in cancer immunotherapy, he served/serves on Advisory Boards for AstraZeneca, Bristol-Meyers Squibb, Cell Genesys, Dendreon, EMD Serono, Janssen/Johnson and Johnson, MannKind, Micromet, Novartis, PerkinElmer and Pfizer.
He received his BS and MS degrees from the University of Detroit and his PhD from Wayne State University. His fellowship training was with Dr. Steven A. Rosenberg, at the National Cancer Institute, National Institutes of Health, Bethesda, MD. Dr. Fox is an internationally recognized expert on cancer immunotherapy and maintains his position as the Harder Family Chair for Cancer Research, Member and Chief, Laboratory of Molecular and Tumor Immunology, at the Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Cancer Institute.
He is also a member and co-leader of the Tumor Immunology Focus Panel for the Knight Cancer Institute and adjunct associate professor, Department of Molecular Microbiology and Immunology, Oregon Health and Science University.
Dr. Fox brings to UbiVac his experience in moving basic science advances from the bench to the bedside. He has received funding from the National Cancer Institute, Department of Defense, Prostate Cancer Foundation and several other foundations. He has published more than 150 manuscripts and book chapters, served on review committees for the NIH, FDA, philanthropic and governmental organizations in the USA, Europe and Asia, and serves on editorial boards of six scientific journals.
Dr. Fox is past president of the Society for Immunotherapy of Cancer (SITC) and is current chair of the World Immunotherapy Council, a consortium of 22 national and international cancer immunotherapy organizations. In 2015 Dr. Fox received the Visionary/Legacy award from the Society for Immunotherapy of Cancer.
Hong-Ming Hu, PhD
Chief Scientific Officer
Hong-Ming Hu, PhD, has served as UbiVac’s Chief Scientific Officer since founding the company in 2005. Dr. Hu received his BS degree in biochemistry from Fudan University, Shanghai, China. He received his MS degree in Molecular Biology from the Chinese Academy of Science, Shanghai, China and worked with Dr. Vishva Dixit at the Howard Hughes Medical Research Institute at the University of Michigan, before joining the Earle A. Chiles Research Institute in Portland, Oregon. He received his PhD from Oregon Health and Science University and performed research at the Earle A. Chiles Research Institute, where his fellowship training was in tumor immunology and cancer immunotherapy.
Dr. Hu is the inventor of UbiVac’s DRibble and nanoparticle vaccines, and has played a central role in directing the scientific development of UbiVac’s products. He is associate member and Chief, Laboratory of Cancer Immunobiology, at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center.
He also holds adjunct faculty positions in the Department of Radiation Oncology at Oregon Health and Science University and in the Department of Physics, Portland State University, Portland, Oregon. He is also co-director, Center for Cancer Research and Biotherapy, Southeastern University and Nanjing Second Hospital, Nanjing, China. He has received funding from the National Cancer Institute, American Cancer Society and several foundations and has served on review committees for NIH, the Veterans Administration and the Department of Defense.
Chief Financial Officer
Steve Buhaly, serves as UbiVac’s Chief Financial Officer. Named Portland Business Journal's CFO of the year in 2011, Steve brings 15 years of CFO experience from his tenure with three public companies. Prior to joining QORVO a communications chipmaker where he helped raise $1 Billion, increased revenue fivefold, and increase profitability, Buhaly was CFO of Longview Fibre, a timber, pulp and paper company. He also served as both a Chief Financial Officer and Chief Operating Officer of Planar Systems, a manufacturer of flat panel displays, where he began as vice president of the medical business area.
Buhaly earned a Bachelor of Science degree from the University of Washington and a Master of Business Administration from the same.
Bernard A. Fox III, MBA
Chief Operating Officer
Bernard A. Fox III, MBA, serves as UbiVac’s Chief Operating Officer. He has been involved with the company since before its inception in 2005, and helped devise the business strategy to further develop the DRibble technology.
After graduating with bachelor’s degrees in economics and accounting, Mr. Fox continued to work with UbiVac serving various roles until he joined the company on a full-time basis in 2009. He received his master’s in business administration from the University of Oregon’s Executive program.
Additionally, Mr. Fox serves as a consultant for biotech startups and has been involved with advising other small businesses. In 2011 he helped found Revcaster, serving on its board until early 2015 when it was sold; having generated a 80x return to investors in a little more than four years.
Traci L. Hilton, PhD
Vice President of Vaccine Development
Traci L. Hilton, PhD, UbiVac’s vice president of vaccine development, joined the company in 2010. Previously, she held appointments as principal scientist and manager, vaccine production.
Dr. Hilton did her undergraduate study in Biochemistry and Molecular Biology at Reed College, Portland, Oregon, and received her PhD in Pharmacology from the University of Washington, Seattle. She did her post-doctoral work at the Institut de génétique et de biologie moléculaire et cellulaire (IGBMC), Strasbourg, France and College of Pharmacy at Oregon State University, Corvallis, Oregon.